Purple Biotech Ltd. Announces Extraordinary General Meeting of Shareholders

Purple Biotech Ltd. has announced that an Extraordinary General Meeting of Shareholders will be held on December 15, 2025, at 4:30 p.m. Israel time at the company's executive offices in Rehovot, Israel. The primary agenda for the meeting is to approve the grant of equity-based awards to the company's Chief Executive Officer, Mr. Gil Efron, and to each of the company's directors. The awards include options to purchase ordinary shares and restricted stock units (RSUs), with specific terms and conditions outlined in the proxy statement. Shareholders and holders of American Depositary Shares (ADSs) of record as of November 3, 2025, are entitled to vote at the meeting. The company has provided detailed instructions on how to vote, including options for voting in person, by proxy, or electronically. The Board of Directors recommends that shareholders vote in favor of the proposals.